Can-Fite BioPharma Ltd. has announced the completion of a Phase II study design and is preparing to initiate a clinical study for Piclidenoson, a novel treatment for Lowe Syndrome, a rare genetic ...

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...

Soligenix Inc ((SNGX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical ...

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine, marketed as ...

There are multiple different types of drugs available for the treatment of Alzheimer’s disease: cholinesterase inhibitors to treat symptoms from mild to severe, and disease-modifying immunotherapies ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modulator, ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...